Provided by Tiger Fintech (Singapore) Pte. Ltd.

ProKidney Corp.

0.7329
-0.0580-7.33%
Post-market: 0.7300-0.0029-0.40%19:26 EDT
Volume:577.78K
Turnover:430.15K
Market Cap:94.94M
PE:-1.17
High:0.8399
Open:0.8092
Low:0.7328
Close:0.7909
Loading ...

Company Profile

Company Name:
ProKidney Corp.
Exchange:
NASDAQ
Establishment Date:
2015
Employees:
204
Office Location:
2000 Frontis Plaza Blvd.,Suite 250,Winston-Salem,North Carolina,United States
Zip Code:
27103
Fax:
- -
Introduction:
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Directors

Name
Position
Pablo Legorreta
Chairman of the Board, Director
Tim Bertram
Chief Executive Officer and Director
Alan M. Lotvin
Director
Brian J. G. Pereira
Director
Jennifer Fox
Director
John M. Maraganore
Director
Jose Ignacio Jimenez Santos
Director
Uma Sinha
Director
William F. Doyle
Director

Shareholders

Name
Position
Tim Bertram
Chief Executive Officer and Director
Deepak Jain
Chief Operating Officer
James Coulston
Chief Financial Officer
Darin J. Weber
Chief Regulatory Officer, SVP, Global Regulatory, Quality
Todd C. Girolamo
Chief Legal Officer